EMA Authorised: Prevymis (Letermovir) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The EMA authorised Prevymis (letermovir) from Merck Sharp & Dohme B.V. for cytomegalovirus infections. It carries an orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infections

Drugs mentioned

• PREVYMIS (letermovir)

Snippet

Status: Authorised. Therapeutic area: Cytomegalovirus Infections. MAH: Merck Sharp & Dohme B.V.. Decision date: 05/12/2025. Orphan medicine